Dose Escalation Among Rheumatoid Arthritis Patients Treated with Infliximab or Abatacept: Comparison in Claims Data

被引：0
|
作者：
Darkow, Theodore [1 ]
Chastek, Benjamin [2 ]
Rosenblatt, Lisa [1 ]
Trivedi, Digisha [1 ]
Hebden, Tony [1 ]
Henk, Henry [2 ]
Liu, Fang [2 ]
机构：
[1] Bristol Myers Squibb Co, Plainsboro, NJ USA
[2] Innovus, Eden Prairie, MN USA
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1221
引用
收藏
页码：S476 / S476
页数：1
相关论文
共 50 条
  • [1] Outcomes of infliximab dose escalation in patients with rheumatoid arthritis
    Cohen, Stanley B.
    Kremer, Joel M.
    Dandreo, Kimberly J.
    Reed, George W.
    Magner, Robert
    Shan, Ying
    Kafka, Shelly
    DeHoratius, Raphael J.
    Ellis, Lorie
    Parenti, Dennis
    [J]. CLINICAL RHEUMATOLOGY, 2019, 38 (09) : 2501 - 2508
  • [2] Outcomes of infliximab dose escalation in patients with rheumatoid arthritis
    Stanley B. Cohen
    Joel M. Kremer
    Kimberly J. Dandreo
    George W. Reed
    Robert Magner
    Ying Shan
    Shelly Kafka
    Raphael J. DeHoratius
    Lorie Ellis
    Dennis Parenti
    [J]. Clinical Rheumatology, 2019, 38 : 2501 - 2508
  • [3] Dose escalation of infliximab in rheumatoid arthritis
    Haraoui, B
    Cameron, L
    Ouellet, M
    White, B
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 124 (04) : A6 - A6
  • [4] REAL-WORLD INCIDENCE OF BIOLOGIC DOSE ESCALATION AND IMPACT ON BIOLOGIC COSTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH INTRAVENOUS AGENTS ABATACEPT, INFLIXIMAB OR TOCILIZUMAB
    Fowler, R.
    McMorrow, D.
    Smith, D.
    Nadkarni, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 558 - 558
  • [5] Healthcare costs for rheumatoid arthritis patients treated with abatacept, infliximab, or rituximab
    Chapman, Richard H.
    Smith, Daniel
    Semroc, Georgette N.
    Trivedi, Digisha N.
    Rosenblatt, Lisa C.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S464 - S464
  • [6] COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB
    Garces, K.
    Thorne, C.
    Boire, G.
    Chow, A.
    Poulin-Costello, M.
    Walker, V
    Haraoui, B.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A229 - A230
  • [7] Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
    Rahman, Mahboob U.
    Strusberg, Ingrid
    Geusens, Piet
    Berman, Alberto
    Yocum, David
    Baker, Daniel
    Wagner, Carrie
    Han, John
    Westhovens, Rene
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) : 1233 - 1238
  • [8] Prediction of dose escalation for rheumatoid arthritis patients under infliximab treatment
    Van Looy, Stijn
    Cruyssen, Bert Vander
    Meeus, Jeroen
    Wyns, Bart
    Westhovens, Rene
    Durez, Patrick
    Van den Bosch, Filip
    Vastesaeger, Nathan
    Geldhof, Anja
    Boullart, Luc
    De Keyser, Filip
    [J]. ENGINEERING APPLICATIONS OF ARTIFICIAL INTELLIGENCE, 2006, 19 (07) : 819 - 828
  • [9] COMPARISON OF DOSE ESCALATION OF INFLIXIMAB AND THE ADDITION OF TACROLIMUS IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO INFLIXIMAB AND METHOTREXATE COMBINATION THERAPY
    Yonemoto, Y.
    Okamura, K.
    Kaneko, T.
    Kobayashi, T.
    Takagishi, K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 199 - 200
  • [10] Infliximab dose escalation in patients with rheumatoid arthritis in the START study: Influence of Infliximab pharmacokinetics and immunogenicity
    Rahman, M. U.
    Strusberg, I.
    Geusens, P.
    Wagner, C.
    Han, J.
    Westhovens, R.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2007, 66 : 86 - 86
12345